


## Study: GV1001 reduces neurodegeneration and prolongs lifespan in mouse model of Alzheimer's disease

February 15 2024



Effect of GV1001 on aging, telomere maintenance, and long-term memory confirmed via bioinformatics analysis. Credit: *Aging* (2024). DOI: 10.18632/aging.205489



A new research paper titled "GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects" has been <u>published</u> in *Aging*.

GV1001, which mimics the activity of human telomerase reverse transcriptase, protects neural cells from <u>amyloid beta</u> (A $\beta$ ) toxicity and other stressors through extra-telomeric function, as noted in our prior in vitro studies. As per a recent phase II clinical trial, it improves cognitive function in patients with moderate to severe dementia. However, the underlying protective mechanisms remain unclear.

In this new study, researchers Hyun-Hee Park, Hyuk Sung Kwon, Kyu-Yong Lee, Ye Eun Kim, Jeong-Woo Son, Na-Young Choi, Myung-Hoon Han, Dong Woo Park, Sangjae Kim, and Seong-Ho Koh from Hanyang University Guri Hospital, Hanyang University Graduate School of Biomedical Science and Engineering and Teloid Inc. aimed to investigate the effects of GV1001 on <u>neurodegeneration</u>, senescence, and survival in triple transgenic Alzheimer's disease (AD) (3xTg-AD) mice.

" [...] we hypothesized that GV1001 might have anti-aging effects and improve neurodegeneration and senescence in vivo as a possible mechanism for its beneficial effects on AD," the researchers write.

GV1001 (1 mg/kg) was subcutaneously injected into old 3xTg-AD mice thrice a week until the endpoint for sacrifice, and survival was analyzed. Magnetic resonance imaging (MRI) and Prussian blue staining (PBS) were performed to evaluate entry of GV1001 entrance into the brain.

Diverse molecular studies were performed to investigate the effect of GV1001 on neurodegeneration and <u>cellular senescence</u> in AD model mice, with a particular focus on BACE, amyloid beta1-42 (A $\beta$ 1-42), phosphorylated tau, volume of dentate gyrus,  $\beta$ -galactosidase positive cells, telomere length, telomerase activity, and aging-associated proteins.



GV1001 crossed the <u>blood-brain barrier</u>, as confirmed by assessing the status of ferrocenecarboxylic acid-conjugated GV1001 using magnetic resonance imaging and PBS. GV1001 increased the survival of 3xTg-AD mice. It decreased BACE and A $\beta$ 1-42 levels, neurodegeneration (i.e., reduced CA1, CA3 and dentate gyrus volume, decreased levels of senescence-associated  $\beta$ -galactosidase positive cells, and increased telomere length and telomerase activity), and levels of aging-associated proteins.

"We suggest that GV1001 exerts anti-aging effects in 3xTg-AD mice by reducing neurodegeneration and senescence, which contributes to improved survival," the researchers write in conclusion.

**More information:** Hyun-Hee Park et al, GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects, *Aging* (2024). <u>DOI: 10.18632/aging.205489</u>

Provided by Impact Journals LLC

Citation: Study: GV1001 reduces neurodegeneration and prolongs lifespan in mouse model of Alzheimer's disease (2024, February 15) retrieved 28 April 2024 from https://medicalxpress.com/news/2024-02-gv1001-neurodegeneration-prolongs-lifespanmouse.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.